Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 95

Sort by

Sort Order Select

Journal Articles

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Blood (2024) 144 (3): 272–282.

https://doi.org/10.1182/blood.2023022730

Published: 2024

Includes: Supplemental data

Journal Articles

Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

Blood (2024) 144 (1): 74–83.

https://doi.org/10.1182/blood.2024023938

Published: 2024

Includes: Supplemental data

Journal Articles

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

Blood (2024) 143 (26): 2735–2748.

https://doi.org/10.1182/blood.2023021088

Published: 2024

Includes: Supplemental data

Journal Articles

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

Blood (2024) 143 (17): 1738–1751.

https://doi.org/10.1182/blood.2023021952

Published: 2024

Includes: Supplemental data

Journal Articles

Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry

Blood (2024) 143 (14): 1365–1378.

https://doi.org/10.1182/blood.2023023142

Published: 2024

Includes: Supplemental data

Journal Articles

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR :: ABL1 -positive ALL

Blood (2024) 143 (14): 1391–1398.

https://doi.org/10.1182/blood.2023021752

Published: 2024

Includes: Supplemental data

Journal Articles

Reshaping MRD Detection Strategies: Next-Generation Sequencing and High DNA Input Identify Previously Missed Measurable Residual Disease in Peripheral Blood of B-Cell Precursor Acute Lmyphoblastic Leukemia

Sonja Bendig, Sandra Bufe, Birgit Fricke, Constantin Proske, Nikos Darzentas, Britta Kehden, Guranda Chitadze, Claudia D Baldus, Michaela Kotrova, Nicola Goekbuget, Monika Brüggemann

Blood (2023) 142 (Supplement 1): 4354.

https://doi.org/10.1182/blood-2023-174458

Published: 2023

Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2023) 142 (Supplement 1): 635.

https://doi.org/10.1182/blood-2023-173709

Published: 2023

Journal Articles

Molecular Subtypes in BCR::ABL1 -Positive ALL Are Defined By Cellular Origins and Cooperating Genomic Events

Blood (2023) 142 (Supplement 1): 843.

https://doi.org/10.1182/blood-2023-187315

Published: 2023

Journal Articles

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

Blood (2023) 142 (Supplement 1): 203.

https://doi.org/10.1182/blood-2023-173708

Published: 2023

Journal Articles

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

Nicola Goekbuget, Stefan Schwartz, Christoph Faul, Max S. Topp, Marion Subklewe, Andrea Renzelmann, Andrea Stoltefuss, Bernd Hertenstein, Anne Wilke, Simon Raffel, Nadja Jäkel, Vladan Vucinic, Dirk Markus Niemann, Lena Reiser, Hubert Serve, Monika Brüggemann, Andreas Viardot

Blood (2023) 142 (Supplement 1): 964.

https://doi.org/10.1182/blood-2023-180472

Published: 2023

Journal Articles

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Blood (2023) 142 (Supplement 1): 1897.

https://doi.org/10.1182/blood-2023-173707

Published: 2023

Journal Articles

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Blood (2023) 142 (Supplement 1): 828.

https://doi.org/10.1182/blood-2023-179442

Published: 2023

Journal Articles

Pseudoprogression As Adverse Event of Chimeric Antigen Receptor T Cell Therapy

Blood (2023) 142 (Supplement 1): 6935.

https://doi.org/10.1182/blood-2023-189047

Published: 2023

Journal Articles

In-Depth Immune Profiling in Children with BCP-ALL within the AIEOP-BFM ALL 2017 Study

Blood (2023) 142 (Supplement 1): 595.

https://doi.org/10.1182/blood-2023-186998

Published: 2023

Journal Articles

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4190.

https://doi.org/10.1182/blood-2023-185875

Published: 2023

Journal Articles

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Christian Bjoern Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Nösslinger, Michael Baumann, Holger Hebart, Tobias Gaska, Josien C. Regelink, Ellen C. Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marcel Spaargaren, Eric Eldering, Stephan Stilgenbauer, Carsten U. Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater

Blood (2023) 142 (5): 446–459.

https://doi.org/10.1182/blood.2023019634

Published: 2023

Includes: Supplemental data

Journal Articles

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia

Blood (2023) 141 (13): 1640–1644.

https://doi.org/10.1182/blood.2022017249

Published: 2023

Includes: Supplemental data

Journal Articles

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol

Michael Svaton, Aneta Skotnicova, Leona Reznickova, Andrea Rennerova, Tatana Valova, Michaela Kotrova, Vincent H. J. van der Velden, Monika Brüggemann, Nikos Darzentas, Anton W. Langerak, Jan Zuna, Jan Stary, Jan Trka, Eva Fronkova

Blood (2023) 141 (5): 529–533.

https://doi.org/10.1182/blood.2022017003

Published: 2023

Includes: Supplemental data

Journal Articles

Genotyping and Minimal Residual Disease (MRD) Assessment in cfDNA By the Euroclonality-NGS DNA Capture (EC-NDC) Panel in Mantle Cell Lymphoma (MCL)

Blood (2022) 140 (Supplement 1): 3518–3520.

https://doi.org/10.1182/blood-2022-166043

Published: 2022

NARROW

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR :: ABL1 -positive ALL

Reshaping MRD Detection Strategies: Next-Generation Sequencing and High DNA Input Identify Previously Missed Measurable Residual Disease in Peripheral Blood of B-Cell Precursor Acute Lmyphoblastic Leukemia

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Molecular Subtypes in BCR::ABL1 -Positive ALL Are Defined By Cellular Origins and Cooperating Genomic Events

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Pseudoprogression As Adverse Event of Chimeric Antigen Receptor T Cell Therapy

In-Depth Immune Profiling in Children with BCP-ALL within the AIEOP-BFM ALL 2017 Study

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol

Genotyping and Minimal Residual Disease (MRD) Assessment in cfDNA By the Euroclonality-NGS DNA Capture (EC-NDC) Panel in Mantle Cell Lymphoma (MCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only